Testing effectiveness (Phase 2)Study completedNCT00393029
What this trial is testing
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Who this might be right for
Anti-p53 TCR-Gene
National Cancer Institute (NCI) 12